Millipore Sigma Vibrant Logo

474791 InSolution™ MG-132 - CAS 133407-82-6 - Calbiochem

Overview

Replacement Information

Key Specifications Table

Empirical Formula
C₂₆H₄₁N₃O₅

Pricing & Availability

Catalog Number AvailabilityPackaging Qty/Pack Price Quantity
474791-1MG
Retrieving availability...
Limited AvailabilityLimited Availability
Stocked 
Discontinued
Limited Quantities Available
Available
    Remaining : Will advise
      Remaining : Will advise
      Will advise
      Contact Customer Service
      Contact Customer Service

      Plastic ampoule 1 mg
      Retrieving price...
      Price could not be retrieved
      Minimum Quantity is a multiple of
      Maximum Quantity is
      Upon Order Completion More Information
      You Saved ()
       
      Request Pricing
      474791-5MG
      Retrieving availability...
      Limited AvailabilityLimited Availability
      Stocked 
      Discontinued
      Limited Quantities Available
      Available
        Remaining : Will advise
          Remaining : Will advise
          Will advise
          Contact Customer Service
          Contact Customer Service

          Plastic ampoule 5 mg
          Retrieving price...
          Price could not be retrieved
          Minimum Quantity is a multiple of
          Maximum Quantity is
          Upon Order Completion More Information
          You Saved ()
           
          Request Pricing
          Description
          Catalogue Number474791
          Brand Family Calbiochem®
          SynonymsCarbobenzoxy-L-leucyl-L-leucyl-L-leucinal, Z-LLL-CHO, Proteasome Inhibitor XI
          References
          ReferencesMeriin, A.B., et al. 1998. J. Biol. Chem. 273, 6373.
          Adams, J., and Stein, R. 1996. Ann. Rep. Med. Chem. 31, 279.
          Lee, D.H., and Goldberg, A.L. 1996. J. Biol. Chem. 271, 27280.
          Wiertz, E.J.H.J., et al. 1996. Cell 84, 769.
          Read, M.A., et al. 1995. Immunity 2, 493.
          Rock, K.L., et al. 1994. Cell 78, 761.
          Product Information
          CAS number67-68-5, 133407-82-6
          ATP CompetitiveN
          FormLiquid
          FormulationA 10 mM (1 mg/210 µl) or (5mg/1050 µl) solution of MG-132 (Cat. No. 474790) in DMSO.
          Hill FormulaC₂₆H₄₁N₃O₅
          Chemical formulaC₂₆H₄₁N₃O₅
          ReversibleY
          Quality LevelMQ100
          Applications
          Biological Information
          Primary Targetproteasome
          Primary Target IC<sub>50</sub>3 µM in inhibiting NF-κB activation
          Primary Target K<sub>i</sub>4 nM as proteasome inhibitor
          Purity≥98% by HPLC
          Physicochemical Information
          Cell permeableY
          Dimensions
          Materials Information
          Toxicological Information
          Safety Information according to GHS
          Safety Information
          R PhraseR: 36/38

          Irritating to eyes and skin.
          S PhraseS: 26-36-45

          In case of contact with eyes, rinse immediately with plenty of water and seek medical advice.
          Wear suitable protective clothing.
          In case of accident or if you feel unwell, seek medical advice immediately (show the label where possible).
          Product Usage Statements
          Storage and Shipping Information
          Ship Code Blue Ice Only
          Toxicity Irritant
          Storage -20°C
          Protect from Light Protect from light
          Do not freeze Ok to freeze
          Special InstructionsFollowing initial thaw, aliquot and freeze (-20°C).
          Packaging Information
          Packaged under inert gas Packaged under inert gas
          Transport Information
          Supplemental Information
          Specifications

          Documentation

          InSolution™ MG-132 - CAS 133407-82-6 - Calbiochem SDS

          Title

          Safety Data Sheet (SDS) 

          InSolution™ MG-132 - CAS 133407-82-6 - Calbiochem Certificates of Analysis

          TitleLot Number
          474791

          References

          Reference overview
          Meriin, A.B., et al. 1998. J. Biol. Chem. 273, 6373.
          Adams, J., and Stein, R. 1996. Ann. Rep. Med. Chem. 31, 279.
          Lee, D.H., and Goldberg, A.L. 1996. J. Biol. Chem. 271, 27280.
          Wiertz, E.J.H.J., et al. 1996. Cell 84, 769.
          Read, M.A., et al. 1995. Immunity 2, 493.
          Rock, K.L., et al. 1994. Cell 78, 761.

          Brochure

          Title
          In Solution!" Product Flyer

          Citations

          Title
        • Yolanda Fernandez, et al. (2006) Chemical Blockage of the Proteasome Inhibitory Function of Bortezomib: Impact on Tumor Cell Death. Journal of Biological Chemistry 281, 1107-1118.
        • Markus D. Lacher, et al. (2006) Transforming Growth Factor-{beta} Receptor Inhibition Enhances Adenoviral Infectability of Carcinoma Cells via Up-Regulation of Coxsackie and Adenovirus Receptor in Conjunction with Reversal of Epithelial-Mesenchymal Transition. Cancer Research 66, 1648-1657.
        • Liwei Chen, et al. (2005) Chemical ablation of androgen receptor in prostate cancer cells by the histone deacetylase inhibitor LAQ824. Molecular Cancer Therapeutics 4, 1311-1319.
        • Emily I. Chen, et al. (2005) Maspin alters the carcinoma proteome. FASEB Journal in press,.
        • Siva Kumar Kolluri, et al. (2005) The R-enantiomer of the nonsteroidal antiinflammatory drug etodolac binds retinoid X receptor and induces tumor-selective apoptosis. Procedings of the National Academy of Science 102, 2525-2530.
        • Zaibo Li, et al. (2005) VHL protein-interacting deubiquitinating enzyme 2 deubiquitinates and stabilizes HIF-1α. European Molecular Biology Organization Reports 6, 373-378.
        • Yasuyuki Miyake, et al. (2005) Novel splicing variant of mouse orc1 is deficient in nuclear translocation and resistant for proteasome-mediated degradation. Journal of Biological Chemistry 280, 12643-12652.
        • Chuan-Jin Wu, et al. (2005) TNF-α induced c-IAP1/TRAF2 complex translocation to a Ubc6-containing compartment and TRAF2 ubiquitination. European Molecular Biology Organization Journal 24, 1886-1898.
        • Zhigang Zhang, Jin-Ying Wu, William Hait and Jin-Ming Yang. (2004) Regulation of the stability of P-glycoprotein by ubiquitination.. Molecular Pharmacology 66, 395-403.
        • Gloria Bonuccelli, et al. (2003) Proteasome inhibitor (MG-132) treatment of mdx mice rescues the expression and membrane localization of dystrophin and dystrophin-associated proteins. American Journal of Pathology 163, 1663-1675.
        • Data Sheet

          Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

          Revision03-June-2013 JSW
          SynonymsCarbobenzoxy-L-leucyl-L-leucyl-L-leucinal, Z-LLL-CHO, Proteasome Inhibitor XI
          DescriptionPotent, reversible, and cell-permeable proteasome inhibitor (Ki = 4 nM). Reduces the degradation of ubiquitin-conjugated proteins in mammalian cells and permeable stains of yeast by the 26S complex without affecting its ATPase or isopeptidase activities. Activates c-Jun N-terminal kinase (JNK1) and inhibits NF-κB activation (IC50 = 3 µM).
          FormLiquid
          FormulationA 10 mM (1 mg/210 µl) or (5mg/1050 µl) solution of MG-132 (Cat. No. 474790) in DMSO.
          Intert gas (Yes/No) Packaged under inert gas
          CAS number67-68-5, 133407-82-6
          Chemical formulaC₂₆H₄₁N₃O₅
          Purity≥98% by HPLC
          Storage -20°C
          Protect from light
          Do Not Freeze Ok to freeze
          Special InstructionsFollowing initial thaw, aliquot and freeze (-20°C).
          Toxicity Irritant
          ReferencesMeriin, A.B., et al. 1998. J. Biol. Chem. 273, 6373.
          Adams, J., and Stein, R. 1996. Ann. Rep. Med. Chem. 31, 279.
          Lee, D.H., and Goldberg, A.L. 1996. J. Biol. Chem. 271, 27280.
          Wiertz, E.J.H.J., et al. 1996. Cell 84, 769.
          Read, M.A., et al. 1995. Immunity 2, 493.
          Rock, K.L., et al. 1994. Cell 78, 761.
          Citation
        • Yolanda Fernandez, et al. (2006) Chemical Blockage of the Proteasome Inhibitory Function of Bortezomib: Impact on Tumor Cell Death. Journal of Biological Chemistry 281, 1107-1118.
        • Markus D. Lacher, et al. (2006) Transforming Growth Factor-{beta} Receptor Inhibition Enhances Adenoviral Infectability of Carcinoma Cells via Up-Regulation of Coxsackie and Adenovirus Receptor in Conjunction with Reversal of Epithelial-Mesenchymal Transition. Cancer Research 66, 1648-1657.
        • Liwei Chen, et al. (2005) Chemical ablation of androgen receptor in prostate cancer cells by the histone deacetylase inhibitor LAQ824. Molecular Cancer Therapeutics 4, 1311-1319.
        • Emily I. Chen, et al. (2005) Maspin alters the carcinoma proteome. FASEB Journal in press,.
        • Siva Kumar Kolluri, et al. (2005) The R-enantiomer of the nonsteroidal antiinflammatory drug etodolac binds retinoid X receptor and induces tumor-selective apoptosis. Procedings of the National Academy of Science 102, 2525-2530.
        • Zaibo Li, et al. (2005) VHL protein-interacting deubiquitinating enzyme 2 deubiquitinates and stabilizes HIF-1α. European Molecular Biology Organization Reports 6, 373-378.
        • Yasuyuki Miyake, et al. (2005) Novel splicing variant of mouse orc1 is deficient in nuclear translocation and resistant for proteasome-mediated degradation. Journal of Biological Chemistry 280, 12643-12652.
        • Chuan-Jin Wu, et al. (2005) TNF-α induced c-IAP1/TRAF2 complex translocation to a Ubc6-containing compartment and TRAF2 ubiquitination. European Molecular Biology Organization Journal 24, 1886-1898.
        • Zhigang Zhang, Jin-Ying Wu, William Hait and Jin-Ming Yang. (2004) Regulation of the stability of P-glycoprotein by ubiquitination.. Molecular Pharmacology 66, 395-403.
        • Gloria Bonuccelli, et al. (2003) Proteasome inhibitor (MG-132) treatment of mdx mice rescues the expression and membrane localization of dystrophin and dystrophin-associated proteins. American Journal of Pathology 163, 1663-1675.